{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:08:44Z","timestamp":1790064524791,"version":"4.0.1"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Gastrointestinal adverse reactions occur in up to 71.8% of patients receiving anti-tuberculosis drugs (ATDs), and acid-suppressing agents are frequently co-prescribed to alleviate these symptoms. Direct evidence from human studies demonstrates that ATDs alone reduce gut microbial diversity, deplete short-chain fatty acid (SCFA)-producing bacteria, and promote opportunistic pathogen overgrowth. Concurrently, acid suppressants, particularly proton pump inhibitors (PPIs), raise intragastric pH and facilitate oral-to-gut translocation of bacteria, independently disrupting microbiota composition and metabolic pathways. In this review, we systematically examine the distinct effects of ATDs and acid suppressants on the gut microbiota, the role of the gut-lung axis in tuberculosis immunity, and, on the basis of mechanistic evidence, propose a theoretical cascade under dual exposure: synergistic microbiota depletion, dual metabolic pathway inhibition, immune homeostasis imbalance, and potentially worsened clinical outcomes. This cascade represents a hypothesis-generating framework derived from preclinical and mechanistic studies, rather than an established clinical pathway, and the critical links from dysbiosis to delayed sputum conversion, poor lesion resolution, or increased drug-induced liver injury currently lack direct human confirmation. On the basis of the available evidence, we recommend that clinicians strictly follow indications for acid suppressants, prefer H\u2082 receptor antagonists(H\n                    <jats:sub>2<\/jats:sub>\n                    RAs) over PPIs, and limit treatment to the shortest effective duration. Probiotics and other microbiota-targeted interventions show promise as adjunctive strategies, but their long-term efficacy remains to be validated. Large-scale prospective studies are urgently needed to test the hypothesized cascade, confirm the direct impact of combined therapy on treatment outcomes, and establish microbiota-based biomarkers for predicting therapeutic response.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1959574","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:57:51Z","timestamp":1790063871000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From microbiome to outcome: the cascading effects of combining acid suppressants with anti-tuberculosis therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Shiyu","family":"Fang","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoman","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","volume-title":"Global Tuberculosis report 2025","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4103\/picr.picr_20_24","article-title":"Incidence of adverse drug reactions among tuberculosis patients initiated on daily drug regimen in a southern district of Karnataka","volume":"16","author":"Kumar","year":"2024","journal-title":"Perspect Clin Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12879-025-10800-1","article-title":"Changes in gut microbiome following anti-tuberculosis treatment: a prospective cohort from eastern China","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12879-025-12369-1","article-title":"The impact of tuberculosis and its treatment on the lung and gut microbiota: a global systematic review, meta-analysis, and amplicon-based metagenomic meta-analysis","volume":"26","author":"Mbabazi","year":"2025","journal-title":"BMC Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/gutjnl-2023-330883","article-title":"Proton pump inhibitors alter gut microbiota by promoting oral microbiota translocation: a prospective interventional study","volume":"73","author":"Xiao","year":"2024","journal-title":"Gut"},{"key":"B7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","article-title":"Proton pump inhibitors alter the composition of the gut microbiota","volume":"65","author":"Jackson","year":"2016","journal-title":"Gut"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1657865","DOI":"10.3389\/fmicb.2025.1657865","article-title":"Proton pump inhibitors and gut microbiota dysbiosis: insights into the pathogenesis of ulcerative colitis","volume":"16","author":"Cao","year":"2025","journal-title":"Front Microbiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/2049-2618-2-42","article-title":"Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for clostridium difficile susceptibility","volume":"2","author":"Seto","year":"2014","journal-title":"Microbiome"},{"key":"B10","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/cm9.0000000000003148","article-title":"Impact of short-term proton pump inhibitors vs. Histamine-2 receptor antagonists on gut microbiota in patients with acute coronary syndrome: a multicenter randomized trial","volume":"138","author":"Chen","year":"2025","journal-title":"Chin Med J (Engl)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1002\/eji.202048556","article-title":"Intestinal microbiota disruption limits the isoniazid mediated clearance of mycobacterium tuberculosis in mice","volume":"50","author":"Negi","year":"2020","journal-title":"Eur J Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0336337","DOI":"10.1371\/journal.pone.0336337","article-title":"Exploring gut microbiota and its predicted functions in pulmonary tuberculosis: a multi-regional study using public 16S datasets","volume":"20","author":"Baral","year":"2025","journal-title":"PLoS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40168-017-0286-2","article-title":"Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy","volume":"5","author":"Namasivayam","year":"2017","journal-title":"Microbiome"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41467-021-21475-y","article-title":"Gastrointestinal microbiota composition predicts peripheral inflammatory state during treatment of human tuberculosis","volume":"12","author":"Wipperman","year":"2021","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12866-026-04882-3","article-title":"Gut microbiome disruption in Tanzanian pulmonary tuberculosis patients: links to treatment, nutritional status, and host immunity","volume":"26","author":"Kullaya","year":"2026","journal-title":"BMC Microbiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e01420","DOI":"10.1128\/mbio.01420-18","article-title":"The microbiome and tuberculosis: early evidence for cross talk","volume":"9","author":"Namasivayam","year":"2018","journal-title":"mBio"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s10096-016-2654-4","article-title":"Microbiome diversity in the sputum of patients with pulmonary tuberculosis","volume":"35","author":"Krishna","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41385-019-0147-3","article-title":"Intestinal dysbiosis compromises alveolar macrophage immunity to mycobacterium tuberculosis","volume":"12","author":"Khan","year":"2019","journal-title":"Mucosal Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jinf.2018.08.006","article-title":"Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs","volume":"78","author":"Hu","year":"2019","journal-title":"J Infect"},{"key":"B20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/s12887-019-1782-2","article-title":"Characterization of gut microbiota in children with pulmonary tuberculosis","volume":"19","author":"Li","year":"2019","journal-title":"BMC Pediatr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e13068","DOI":"10.1111\/eci.13068","article-title":"Systemic proinflammation after mycobacterium tuberculosis infection was correlated to the gut microbiome in HIV-uninfected humans","volume":"49","author":"Huang","year":"2019","journal-title":"Eur J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0061521","DOI":"10.1128\/spectrum.00615-21","article-title":"Gut mycobiota dysbiosis in pulmonary tuberculosis patients undergoing anti-tuberculosis treatment","volume":"9","author":"Cao","year":"2021","journal-title":"Microbiol Spectr"},{"key":"B23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/1462-2920.14015","article-title":"Gut microbiome contributes to impairment of immunity in pulmonary tuberculosis patients by alteration of butyrate and propionate producers","volume":"20","author":"Maji","year":"2018","journal-title":"Environ Microbiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/19490976.2015.1134082","article-title":"Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism","volume":"7","author":"Morrison","year":"2016","journal-title":"Gut Microbes"},{"key":"B25","doi-asserted-by":"publisher","first-page":"822","DOI":"10.3389\/fphys.2017.00822","article-title":"Alternation of gut microbiota in patients with pulmonary tuberculosis","volume":"8","author":"Luo","year":"2017","journal-title":"Front Physiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e00325","DOI":"10.14309\/ctg.0000000000000325","article-title":"Influence of proton pump inhibitors and histamine receptor 2 antagonists on blastocystis ST3 and selected microorganisms of intestinal microbiota in vitro","volume":"12","author":"Lepczy\u0144ska","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.3390\/biomedicines12102271","article-title":"Proton pump inhibitors and oral-gut microbiota: from mechanism to clinical significance","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomedicines"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1781831","DOI":"10.3389\/fcimb.2026.1781831","article-title":"Proton pump inhibitor exposure modulates functional and transcriptional responses in lactobacillus acidophilus: a comprehensive computational and experimental insights","volume":"16","author":"Naorem","year":"2026","journal-title":"Front Cell Infect Microbiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.rgmxen.2025.09.003","article-title":"Systematic review: effect of proton pump inhibitors on helicobacter pylori physiology","volume":"90","author":"Bland\u00f3n-Arias","year":"2025","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nri3535","article-title":"Microbiota-mediated colonization resistance against intestinal pathogens","volume":"13","author":"Buffie","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/gutjnl-2017-315306","article-title":"Proton pump inhibitor use associated with changes in gut microbiota composition","volume":"67","author":"Reveles","year":"2018","journal-title":"Gut"},{"key":"B32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.11622\/smedj.2018152","article-title":"Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore","volume":"60","author":"Koo","year":"2019","journal-title":"Singapore Med J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1205490","DOI":"10.3389\/fendo.2023.1205490","article-title":"Evidence for proton-pump inhibitor (PPI)-associated dysbiosis in metabolically unhealthy obesity","volume":"14","author":"Burmeister","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e23541","DOI":"10.1096\/fj.202302558r","article-title":"Alterations in gut microbiota and bile acids by proton-pump inhibitor use and possible mediating effects on elevated glucose levels and insulin resistance","volume":"38","author":"He","year":"2024","journal-title":"FASEB J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s43440-023-00489-x","article-title":"Proton pump inhibitor-induced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics","volume":"75","author":"Kiecka","year":"2023","journal-title":"Pharmacol Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001539","article-title":"Bile acid signaling in MASLD: from pathogenesis to therapeutic applications","author":"Simbrunner","year":"2025","journal-title":"Hepatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/mco.0000000000000709","article-title":"Emerging roles of bile acids in control of intestinal functions","volume":"24","author":"Yang","year":"2021","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e70064","DOI":"10.1111\/hel.70064","article-title":"Resilience of the gut microbiome to short proton pump inhibitor therapy with or without high-dosage L. Reuteri in H. Pylori-infected adults","volume":"30","author":"Bibb\u00f2","year":"2025","journal-title":"Helicobacter"},{"key":"B39","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3390\/microorganisms9020286","article-title":"Anti-acid drug treatment induces changes in the gut microbiome composition of hemodialysis patients","volume":"9","author":"Lin","year":"2021","journal-title":"Microorganisms"},{"key":"B40","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrmicro.2016.142","article-title":"Emerging pathogenic links between microbiota and the gut-lung axis","volume":"15","author":"Budden","year":"2017","journal-title":"Nat Rev Microbiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e1013603","DOI":"10.1371\/journal.ppat.1013603","article-title":"The microbiome and gut-lung axis in nontuberculous mycobacterial pulmonary disease","volume":"21","author":"Thompson","year":"2025","journal-title":"PLoS Pathog"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e1009377","DOI":"10.1371\/journal.ppat.1009377","article-title":"Microbiome-immune interactions in tuberculosis","volume":"17","author":"Mori","year":"2021","journal-title":"PLoS Pathog"},{"key":"B44","doi-asserted-by":"publisher","first-page":"100364","DOI":"10.1016\/j.mucimm.2026.100364","article-title":"From the gut to the lung: microbiota-associated metabolites as regulators of respiratory immunometabolism","author":"Xiang","year":"2026","journal-title":"Mucosal Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"117556","DOI":"10.1016\/j.celrep.2026.117556","article-title":"Microbial metabolites at the front line: orchestrating gastrointestinal and systemic barrier immunity across the lifespan","volume":"45","author":"Koren","year":"2026","journal-title":"Cell Rep"},{"key":"B46","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41385-019-0160-6","article-title":"Microbes, metabolites, and the gut-lung axis","volume":"12","author":"Dang","year":"2019","journal-title":"Mucosal Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"14648","DOI":"10.1021\/acsomega.3c05846","article-title":"Short-chain fatty acid (SCFA) as a connecting link between microbiota and gut-lung axis-A potential therapeutic intervention to improve lung health","volume":"9","author":"Verma","year":"2024","journal-title":"ACS Omega"},{"key":"B48","doi-asserted-by":"publisher","first-page":"L65","DOI":"10.1152\/ajplung.00421.2020","article-title":"Lung immune tone via gut-lung axis: gut-derived LPS and short-chain fatty acids' Immunometabolic regulation of lung IL-1\u03b2, FFAR2, and FFAR3 expression","volume":"321","author":"Liu","year":"2021","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"106311","DOI":"10.1016\/j.micpath.2023.106311","article-title":"Gut microbiota regulate migration of lymphocytes from gut to lung","volume":"183","author":"Ni","year":"2023","journal-title":"Microb Pathog"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e00109","DOI":"10.1128\/iai.00109-18","article-title":"Tumor necrosis factor alpha antagonism reveals a gut\/lung axis that amplifies regulatory T cells in a pulmonary fungal infection","volume":"86","author":"Tweedle","year":"2018","journal-title":"Infect Immun"},{"key":"B51","doi-asserted-by":"publisher","first-page":"741934","DOI":"10.3389\/fimmu.2021.741934","article-title":"Stigmasterol restores the balance of Treg\/Th17 cells by activating the Butyrate-PPAR\u03b3 axis in colitis","volume":"12","author":"Wen","year":"2021","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.mucimm.2023.05.005","article-title":"Butyrate regulates neutrophil homeostasis and impairs early antimicrobial activity in the lung","volume":"16","author":"Dang","year":"2023","journal-title":"Mucosal Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"110231","DOI":"10.1016\/j.cbi.2022.110231","article-title":"Short chain fatty acids: fundamental mediators of the gut-lung axis and their involvement in pulmonary diseases","volume":"368","author":"Ashique","year":"2022","journal-title":"Chem Biol Interact"},{"key":"B54","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.chom.2017.03.003","article-title":"Anaerobic bacterial fermentation products increase tuberculosis risk in antiretroviral-drug-treated HIV patients","volume":"21","author":"Segal","year":"2017","journal-title":"Cell Host Microbe"},{"key":"B55","doi-asserted-by":"publisher","first-page":"773261","DOI":"10.3389\/fimmu.2022.773261","article-title":"Acetate improves the killing of streptococcus pneumoniae by alveolar macrophages via NLRP3 inflammasome and Glycolysis-HIF-1\u03b1 axis","volume":"13","author":"Machado","year":"2022","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/sji.12515","article-title":"The inflammation induced by lipopolysaccharide can be mitigated by short-chain fatty acid, butyrate, through upregulation of IL-10 in septic shock","volume":"85","author":"Wang","year":"2017","journal-title":"Scand J Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1007\/s10620-012-2259-4","article-title":"Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein claudin-1 transcription","volume":"57","author":"Wang","year":"2012","journal-title":"Dig Dis Sci"},{"key":"B58","doi-asserted-by":"publisher","first-page":"154220","DOI":"10.1016\/j.tox.2025.154220","article-title":"Sorafenib induces intestinal toxicity by disturbing gut microbiota and activating the LPS\/TLR4\/NF-\u03baB signaling pathway in mice","volume":"517","author":"Xu","year":"2025","journal-title":"Toxicology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41387-024-00306-1","article-title":"Ginger essential oil prevents NASH progression by blocking the NLRP3 inflammasome and remodeling the gut microbiota-LPS-TLR4 pathway in mice","volume":"14","author":"Panyod","year":"2024","journal-title":"Nutr Diabetes"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.3389\/fmicb.2019.01795","article-title":"Infection of dendritic cells with mycobacterium avium subspecies hominissuis exhibits a functionally tolerogenic phenotype in response to toll-like receptor agonists via IL-10\/Cox2\/PGE2\/EP2 axis","volume":"10","author":"Kim","year":"2019","journal-title":"Front Microbiol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"6132289","DOI":"10.1155\/2022\/6132289","article-title":"Sishen pill ameliorates dextran sulfate sodium (DSS)-induced colitis with spleen-kidney yang deficiency syndromes: role of gut microbiota, fecal metabolites, inflammatory dendritic cells, and TLR4\/NF-\u03baB pathway","volume":"2022","author":"Ge","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.3390\/ijms26199663","article-title":"The gut microbiome-trained immunity circuit in inflammatory bowel diseases","volume":"26","author":"Yang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e32831","DOI":"10.1016\/j.heliyon.2024.e32831","article-title":"How aging influences the gut-bone marrow axis and alters hematopoietic stem cell regulation","volume":"10","author":"Wells","year":"2024","journal-title":"Heliyon"},{"key":"B64","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41467-025-67169-7","article-title":"Chemotherapy-driven intestinal dysbiosis and indole-3-propionic acid rewire myelopoiesis to promote a metastasis-refractory state","volume":"17","author":"Bersier","year":"2025","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4049\/jimmunol.2001304","article-title":"Gut microbiota regulate gut-lung axis inflammatory responses by mediating ILC2 compartmental migration","volume":"207","author":"Pu","year":"2021","journal-title":"J Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.cell.2024.11.020","article-title":"A gut commensal protozoan determines respiratory disease outcomes by shaping pulmonary immunity","volume":"188","author":"Burrows","year":"2025","journal-title":"Cell"},{"key":"B67","doi-asserted-by":"publisher","first-page":"7600","DOI":"10.1038\/s41467-022-35347-6","article-title":"Maturation and specialization of group 2 innate lymphoid cells through the lung-gut axis","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1595486","DOI":"10.3389\/fimmu.2025.1595486","article-title":"Bile acid-mediated gut-liver axis crosstalk: the role of nuclear receptor signaling in dynamic regulation of inflammatory networks","volume":"16","author":"Yan","year":"2025","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B70","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41586-019-1276-2","article-title":"Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis","volume":"570","author":"Ardain","year":"2019","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1831258","DOI":"10.3389\/fimmu.2026.1831258","article-title":"Beyond dysbiosis: microbial metabolites as key remodelers of nasal mucosal immune tolerance in chronic rhinosinusitis","volume":"17","author":"Huang","year":"2026","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00253-024-13280-6","article-title":"Rifaximin ameliorates influenza A virus infection-induced lung barrier damage by regulating gut microbiota","volume":"108","author":"Zhang","year":"2024","journal-title":"Appl Microbiol Biotechnol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"113929","DOI":"10.1016\/j.isci.2025.113929","article-title":"Bile acid receptor Tgr5 prevents macrophage hyperinflammation during bacterial sepsis through metabolic and epigenetic silencing","volume":"28","author":"Reich","year":"2025","journal-title":"iScience"},{"key":"B74","doi-asserted-by":"publisher","first-page":"108087","DOI":"10.1016\/j.micpath.2025.108087","article-title":"The gut-lung axis in tuberculosis: a new frontier in immunomodulation and microbiota-directed therapeutic strategies","volume":"209","author":"Nasare","year":"2025","journal-title":"Microb Pathog"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3760\/cma.j.cn112147-20240614-00338","article-title":"Guidelines for diagnosis and management of drug-induced liver injury caused by anti-tuberculosis drugs (2024 version)","volume":"47","year":"2024","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"B76","doi-asserted-by":"publisher","first-page":"101355","DOI":"10.1016\/j.jcmgh.2024.05.003","article-title":"Interplay between drug-induced liver injury and gut microbiota: a comprehensive overview","volume":"18","author":"Li","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/hep.1840050414","article-title":"Cimetidine inhibits the formation of the reactive, toxic metabolite of isoniazid in rats but not in man","volume":"5","author":"Lauterburg","year":"1985","journal-title":"Hepatology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e0068323","DOI":"10.1128\/aac.00683-23","article-title":"Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis","volume":"67","author":"Stemkens","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1111\/j.1530-0277.2011.01487.x","article-title":"Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice","volume":"35","author":"Inokuchi","year":"2011","journal-title":"Alcohol Clin Exp Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/ar.25562","article-title":"Lipopolysaccharide, arbiter of the gut-liver axis, modulates hepatic cell pathophysiology in alcoholism","volume":"308","author":"Mak","year":"2025","journal-title":"Anat Rec (Hoboken)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"109214","DOI":"10.1016\/j.fsi.2023.109214","article-title":"Butyrate induces STAT3\/HIF-1\u03b1\/IL-22 signaling via GPCR and HDAC3 inhibition to activate autophagy in head kidney macrophages from turbot (Scophthalmus maximus L.)","volume":"143","author":"Zhang","year":"2023","journal-title":"Fish Shellfish Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"10346","DOI":"10.1038\/s41598-017-10346-6","article-title":"Antibiotic treatment for tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed","volume":"7","author":"Wipperman","year":"2017","journal-title":"Sci Rep"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00018-019-03370-4","article-title":"The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty?","volume":"77","author":"Eribo","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"B84","volume-title":"WHO Consolidated guidelines on Tuberculosis: Module 4: Treatment and Care","year":"2025"},{"key":"B85","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"211","author":"Saukkonen","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"9444","DOI":"10.3390\/ijms24119444","article-title":"Regulation of gut microflora by lactobacillus casei Zhang attenuates liver injury in mice caused by anti-tuberculosis drugs","volume":"24","author":"Li","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e2100108","DOI":"10.1002\/mnfr.202100108","article-title":"Lactobacillus casei alleviated the abnormal increase of cholestasis-related liver indices during tuberculosis treatment: a post hoc analysis of randomized controlled trial","volume":"65","author":"Xiong","year":"2021","journal-title":"Mol Nutr Food Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1538528","DOI":"10.3389\/fmed.2025.1538528","article-title":"Bacteroides fragilis 839 ameliorates anti-tuberculosis drugs-induced liver injury by suppressing inflammation and regulating gut microbiota in mice","volume":"12","author":"Li","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B89","doi-asserted-by":"publisher","first-page":"111937","DOI":"10.1016\/j.intimp.2024.111937","article-title":"Adjunctive administration of parabiotic lactobacillus sakei CVL-001 ameliorates drug-induced toxicity and pulmonary inflammation during antibiotic treatment for tuberculosis","volume":"132","author":"Kim","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"114400","DOI":"10.1016\/j.biopha.2023.114400","article-title":"Gut microbiota affects sensitivity to immune-mediated isoniazid-induced liver injury","volume":"160","author":"Liu","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"B91","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1039\/c9fo01583c","article-title":"Efficacy of proprietary lactobacillus casei for anti-tuberculosis associated gastrointestinal adverse reactions in adult patients: a randomized, open-label, dose-response trial","volume":"11","author":"Lin","year":"2020","journal-title":"Food Funct"},{"key":"B92","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1080\/27697061.2025.2531086","article-title":"Effect of probiotics supplementation on clinical, humanistic, and safety outcomes in patients with tuberculosis: a prospective cohort study in a tertiary healthcare facility in South India","volume":"45","author":"Baral","year":"2026","journal-title":"J Am Nutr Assoc"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3390\/nu14081668","article-title":"Lactobacillus casei improve anti-tuberculosis drugs-induced intestinal adverse reactions in rat by modulating gut microbiota and short-chain fatty acids","volume":"14","author":"Li","year":"2022","journal-title":"Nutrients"},{"key":"B94","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.idc.2025.07.007","article-title":"Microbiome therapeutics for clostridioides difficile infection","volume":"39","author":"Lucky","year":"2025","journal-title":"Infect Dis Clin North Am"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3390\/pathogens12091149","article-title":"Exploring the potential of fecal microbiota transplantation as a therapy in tuberculosis and inflammatory bowel disease","volume":"12","author":"Boicean","year":"2023","journal-title":"Pathogens"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2612428","DOI":"10.1080\/19490976.2025.2612428","article-title":"Gut-lung axis and microbiome alterations in mycobacterial infections: from pathogenesis to therapeutic potential","volume":"18","author":"Kang","year":"2026","journal-title":"Gut Microbes"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1959574\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:57:53Z","timestamp":1790063873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1959574\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":96,"alternative-id":["10.3389\/fmed.2026.1959574"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1959574","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1959574"}}